Evidence map›Paper›PMID 29161297›Full record

ArticlePloS one2017

Prognostic performance of MR-pro-adrenomedullin in patients with community acquired pneumonia in the Emergency Department compared to clinical severity scores PSI and CURB.

Jacopo Maria Legramante, Maria Mastropasqua, Beniamino Susi, Ottavia Porzio, Marta Mazza, Grazia Miranda Agrippino, Cartesio D Agostini, Antonella Brandi, Germano Giovagnoli, Vito Nicola Di Lecce and 2 more

Registry-linked trialAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06130046 (MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation), which is not on this map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06130046 recruitingnot on this mapstarted 2022, after this paper: background citation

MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation

TypeobservationalSponsorUniversity of Rome Tor VergataRan2022 to 2026Enrolled300ConditionsKidney Transplant, Complications, Liver Transplant, ComplicationsArmsMR-proADM dosage
3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Circulating MR-proADM levels, as an indicator of endothelial dysfunction, for early risk stratification of mid-term mortality in COVID-19 patients.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Observational
  17. Observational
  18. Article
  19. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jacopo Maria LegramanteEmergency Department, Policlinico Tor Vergata, Roma, Italy.
Maria MastropasquaEmergency Department, Policlinico Tor Vergata, Roma, Italy.
Beniamino SusiEmergency Department, Policlinico Tor Vergata, Roma, Italy.
Ottavia PorzioClinical Laboratory, Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy.
Marta MazzaMedicina e Chirurgia d'Accettazione e d'Urgenza, Ospedale Maria Vittoria, Torino, Italy.
Grazia Miranda AgrippinoMedicina per l'Alta Complessità Assistenziale 3, AOU Careggi, Firenze, Italy.
Cartesio D AgostiniLaboratory of Clinical Microbiology, Policlinico Tor Vergata, Roma, Italy.
Antonella BrandiEmergency Department, Policlinico Tor Vergata, Roma, Italy.
Germano GiovagnoliEmergency Department, Policlinico Tor Vergata, Roma, Italy.
Vito Nicola Di LecceEmergency Department, Policlinico Tor Vergata, Roma, Italy.
Sergio BernardiniDepartment of Experimental Medicine and Surgery, Università di Tor Vergata, Roma, Italy.
Marilena MinieriDepartment of Experimental Medicine and Surgery, Università di Tor Vergata, Roma, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aim(i) evaluate the performance of MR-pro-ADM in reflecting the outcome and risk for CAP patients in the emergency department, and (ii) compare the prognostic performance of MR-pro-ADM with that of clinical scores PSI and CURB65.

methodsObservational prospective, single-center study in patients with suspected community acquired pneumonia (CAP). Eighty one patients underwent full clinical and laboratory assessment as by protocol, and were followed up a 28 days. Primary endpoints measured were: death, death at 14 days, non-invasive mechanical ventilation (NIMV), endotracheal intubation (EI), ICU admission, overall hospital stay >10 days, emergency department stay >4 days. The discriminative performance of MR-pro-ADM and clinical scores was assessed by AUROC analysis.

resultsThe distribution for MR-pro-ADM followed an upward trend, increasing with the increase of both PSI (p<0.001) and CURB65 (p<0.001) classes. However, the difference between MRproADM values and score classes was significant only in the case of CURB65 classes 0 and 1 (p = 0.046), 2 (p = 0.013), and 3 (p = 0.011); and with PSI classes 5, 3 (p = 0.044), and 1 (p = 0.020). As to the differences among variables for the six end-points, MR-pro-ADM values in the two groups selected for each considered end-point differed in a statistically significant manner for all endpoints. Both PSI and CURB65 differed significantly for all end-points, except for stay in the ED longer than 4 days and the hospital stay longer than 10 days and endotracheal intubation (only PSI classes differed with statistical significance). ROC analyses evidenced that MR-pro-ADM values gave the greatest AUC for the prediction of death, endotracheal intubation, hospital stay >10 days and DE stay >4 days, compared to the PSI and CURB (though difference not statistically significant). For each endpoint measured, the best thresholds values for Mr-pro-ADM were: 1.6 (specificity 76.5%; sensitivity 77.8%) for death; 2.5 (specificity 88.9%; sensitivity 80.0%) for death at 14 days; 1.5 (specificity 77.0%; sensitivity 87.5%) for NIMV; 2.4 (specificity 88.7%; sensitivity 83.3%) for endotracheal intubation; 0.9 (specificity 53.5%; sensitivity 70.6%) for DE stay greater than 4 days; 1.9 (specificity 82.1%; sensitivity 55.3%) for hospital stay greater than 10 days. The AUC for the combination of MR-pro-ADM and PSI was 81.29% [63.41%-99.17%], but not in a statistically significant manner compared to the AUCs of the single predictors. Conversely, the AUC for the combination of MR-pro-ADM and CURB65 was 87.58% [75.54%-99.62%], which was significantly greater than the AUC of CURB65 (p = 0.047) or PSI (p = 0.017) alone.

conclusionsThe present study confirms that assessment of MR-pro-ADM levels in CAP patients in addition to CURB scores increases the prognostic accuracy of CURB alone and may help rule out discrepancies arising from flawed clinical severity classification. With particular reference to patients scoring in the upper classes of CURB and PSI, MR-pro-ADM values provided additional information towards a better risk stratification of those patients. In particular, our results pointed towards two MR-pro-ADM threshold values that appear to predict with a good degree of accuracy the patient's need for non-invasive mechanical ventilation, endotracheal intubation, or intensive care. This aspect, however, deserves further investigation.

Indexed as

AdrenomedullinAgedBiomarkersCommunity-Acquired InfectionsCross InfectionEmergency Service, HospitalFemaleHospitalsHumansIntensive Care UnitsMaleMiddle AgedMortalityPeptide FragmentsPneumoniaPrognosisAdrenomedullinBiomarkersmid-regional pro-adrenomedullin, humanPeptide FragmentsProtein Precursors

Identifiers

PMID29161297
PMCPMC5697810

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.